Gianmario Candore has a background in statistics and business economics and over 20 years of experience driving data analytics and observational research initiatives in the private sector and regulatory authorities.
In 2009, Gianmario joined the European Medicines Agency (EMA) where he was involved in numerous projects and strategic initiatives. Within EMA’s pharmacovigilance, Gianmario co-authored the guidance on statistical signal detection, and tested and implemented methodologies used during the COVID-19 vaccines safety monitoring. As part of his work in observational research, he tested the Observational Medical Outcomes Partnership (OMOP) Common Data Model, contributed to the creation of DARWIN EU®, and led the internal real word data transformation to support regulatory decision-making. He was also co-chair of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®).
Gianmario joined Bayer in 2022 where is leading the development of evidence generation from multiple data sources, and he is involved in identifying strategic partnerships, enabling the advancement of innovative methodologies and in the coordination of evidence generation activities.